Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP)

BMC Health Services Research

Research

Daoud Al-Badriyeh¹  Ayman Saleh²  Zakiya Al-Boloshi³  Honar Cherif⁴  Javid Gaziev⁴  Kakil Rasul⁵  Salha Bujassoum⁵  Amid Abu Hmaidan⁶  Anas Hamad⁷  Shereen Elazzazy⁷  Moza Al-Hail⁸  Yolande Hanssens⁸  Hadi Abu Rasheed⁹  Ahmed Babiker^1,10 

[1] College of Pharmacy, QU Health, Qatar University, PO Box 2713, Doha, Qatar;Division of Pediatric Hematology/Oncology, Sidra Medicine, PO Box 26999, Doha, Qatar;Drug Supply Department, Hamad Medical Corporation, PO Box 3050, Doha, Qatar;Hematology Department, National Center for Cancer Care & Research, Hamad Medical Corporation, PO Box 3050, Doha, Qatar;Medical Oncology Department, National Center for Cancer Care & Research, Hamad Medical Corporation, PO Box 3050, Doha, Qatar;National Cancer Program, Directorate of Policy, Ministry of Public Health, PO Box 42, Doha, Qatar;Pharmacy Department, National Center for Cancer Care & Research, Hamad Medical Corporation, PO Box 3050, Doha, Qatar;Pharmacy Executive Office, Hamad Medical Corporation, PO Box 3050, Doha, Qatar;Professional Development & Scientific Research Department, Qatar Cancer Society, PO Box 22944, Doha, Qatar;Registration & Drugs Pricing Section, Pharmacy & Drug Control Department, Ministry of Public Health, PO Box 42, Doha, Qatar;

关键词: Patient access;    Patient-reported outcomes;    Cancer;    Hematology;    Oncology;    Precision medicine;    Health economics;    Pharmaceutical procurement;    Health policy;    Qatar;   

DOI  :  10.1186/s12913-022-08981-5

 received in 2022-06-24, accepted in 2022-12-16,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundIn line with global trends, cancer incidence and mortality may have decreased for specific types of cancer in Qatar. However, the cancer-related burden on patients, healthcare systems, and the economy is expected to expand; thus, cancer remains a significant public healthcare issue in Qatar. Qatar’s free access to cancer care represents a considerable economic burden. Ensuring the best utilization of financial resources in the healthcare sector is important to provide unified and fair access to cancer care for all patients. Experts from the Qatar Oncology Health Economics Expert Panel (Q-OHEP) aimed to establish a consistent and robust base for evaluating oncology/hematology medications; involve patients’ insights to accelerate access to cutting-edge medications; increase the value of cancer care; and reach a consensus for using cost-effective strategies and efficient methodologies in cancer treatment.MethodsThe Q-OHEP convened on 30 November 2021 for a 3-hour meeting to discuss cancer management, therapeutics, and health economics in Qatar, focusing on four domains: (1) regulatory, (2) procurement, (3) treatment, and (4) patients. Discussions, guided by a moderator, focused on a list of suggested open-ended questions.ResultsSome of the salient recommendations included the development of a formal, fast-track, preliminary approval pathway for drugs needed by patients with severe disease or in critical condition; and encouraging and promoting the conduct of local clinical trials and real-world observational studies using existing registry data. The Q-OHEP also recommended implementing a forecast system using treatment center data based on the supply/demand of formulary oncology drugs to detect treatment patterns, estimate needs, expedite procurement, and prevent shortages/delays. Furthermore, the panel discussed the needs to define value concerning cancer treatment in Qatar, implement value-based models for reimbursement decision-making such as health technology assessment and multiple-criteria decision analysis, and promote patient education and involvement/feedback in developing and implementing cancer management guidelines.ConclusionHerein, we summarize the first Q-OHEP consensus recommendations, which aim to provide a solid basis for evaluating, registering, and approving new cancer medications to accelerate patient access to novel cancer treatments in Qatar; promote/facilitate the adoption and collection of patient-reported outcomes; and implement value-based cancer care in Qatar.

【 授权许可】

CC BY   
© The Author(s) 2023